This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This is a Phase II, open-label study designed to study whether long-term maintenance with pegylated-interferon alfa 2a (PEG-IFN) reduces the rate of liver fibrosis progression in subjects with HCV/HIV co-infection. Both HCV treatment nanve and previously treated subjects will be enrolled. Up to 180 subjects nationwide are expected to participate with ten subjects targeted for recruitment at this site. The study duration will be between 72 and 96 weeks and will require about 18 visits depending on which arm of the study subjects participate. Study procedures will include physical exams, blood and urine tests, several outcomes assessments, and EKG (if indicated), an eye exm (if indicated), and liver biopsies.
Showing the most recent 10 out of 767 publications
